...Feilong Tan; Li Zhou; Guijiang Huang; Yanhua Li; Wenjie Yin; Hongying Xia Introduction: Pembrolizumab is a PD-1 inhibitor that has been approved for the treatment of melanoma, non-small cell lung cancer, esophageal cancer and other malignant tumors. The safety profile of pembrolizumab across...

... inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer, but its relationship with BMI on survival outcomes is unclear. Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from...

... Miyata Introduction: Metastatic or unresectable locally advanced oesophageal cancer remains a disease with high mortality. More recently, pembrolizumab plus chemotherapy has been indicated as the first-line treatment for those patients, but the predictive factors for treatment efficacy remain...

...; Fumihiko Urabe; Keiichiro Mori; Takafumi Yanagisawa; Shunsuke Tsuduki; Kyoshi Takahara; Teruo Inamoto; Jun Miki; Takahiro Kimura; Yoshio Ohno; Ryoichi Shiroki; Haruhito Azuma Introduction: It is well known that patients with objective response to pembrolizumab have a durable duration of response, leading...

... Kagamu Introduction: Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination) remain undetermined. We aimed to evaluate...

...Yuko Kanbayashi; Momoko Kobayashi; Miku Anzai; Tadashi Shimizu; Mayako Uchida Background: Pembrolizumab has been widely used in patients since its release, but detailed information on lung-specific adverse events (AEs) from post-marketing monitoring has not been reported. Objectives: This study...

... of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors. Methods: Eighty patients treated with pembrolizumab or atezolizumab...

... death-ligand 1 (PD-L1) expression undergoing first-line pembrolizumab monotherapy for NSCLC. Methods: We reviewed data from 133 patients with high PD-L1 expression undergoing first-line pembrolizumab monotherapy for NSCLC at 6 Japanese centers between February 2017 and December 2018. The correlations...

... of the Geriatric Nutritional Risk Index (GNRI) in second-line pembrolizumab (PEM) therapy for patients with metastatic urothelial carcinoma (mUC). Patients and Methods: From January 2018 to October 2019, 52 mUC patients, treated previously with platinum-based chemotherapy, underwent second-line PEM therapy...

... death protein 1 (PD-1) inhibitors in patients with urothelial cancer. We therefore evaluated the relationship between irAEs and pembrolizumab efficacy in urothelial cancer patients. Methods: Patients with urothelial cancer who were treated with pembrolizumab in a second-line setting or later between...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pneumonitis Nivolumab Pembrolizumab Immunotherapy Table 2...

... of anti-PD-1 antibody could control these small intrahepatic metastatic nodules. In a nonclinical study, the combination of pembrolizumab and lenvatinib inhibited the cancer immunosuppressive environments induced by tumor-associated macrophages and regulatory T cells. This, in turn, decreased the levels...

... cohorts of a phase I/II trial of the anti-PD-1 antibody nivolumab in advanced HCC showed favorable results. Two phase III studies are currently ongoing: a comparison of nivolumab and sorafenib in the first-line setting for advanced HCC, and a comparison of the anti-PD-1 antibody pembrolizumab...